Veradigm (MDRX) Stock Price

Veradigm Price

NASDAQ·CLOSED
4.80USD+0.05 (+1.05 %)
Market closed

Over the last 19 years Veradigm grew revenue by 10.7% annually, reaching 588.02 M USD. Earnings per share have grown at 16.3% per year over the last 17 years. For Veradigm, the net margin of -14.7% is down versus 22.5% a few years ago. The consensus 12-month price target for Veradigm is 5.10 USD, about 6.2% above where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 20% above its 52-week low.

Veradigm stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Veradigm over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Veradigm stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Veradigm's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Veradigm Stock Price History
DateVeradigm Price
7/20/20264.80 USD
7/17/20264.75 USD
7/16/20264.90 USD
7/15/20264.75 USD
7/14/20264.90 USD
7/13/20264.76 USD
7/10/20265.05 USD
7/9/20264.75 USD
7/8/20264.76 USD
7/7/20264.75 USD
7/6/20264.65 USD
7/2/20265.10 USD
7/1/20265.00 USD
6/30/20265.09 USD
6/29/20265.00 USD
6/26/20265.10 USD
6/25/20265.10 USD
6/24/20265.00 USD
6/23/20264.95 USD
6/22/20265.00 USD
6/18/20264.80 USD
6/17/20264.80 USD
6/16/20264.80 USD
6/15/20264.85 USD
6/12/20264.80 USD
6/11/20265.18 USD
6/10/20265.10 USD
6/9/20265.10 USD
6/8/20265.10 USD
6/5/20265.00 USD
6/4/20265.10 USD
6/3/20264.75 USD
6/2/20264.50 USD
6/1/20264.90 USD
5/29/20265.00 USD
5/28/20264.90 USD
5/27/20264.90 USD
5/26/20264.75 USD
5/22/20264.75 USD
5/21/20264.75 USD
5/20/20264.75 USD
5/19/20264.75 USD
5/18/20265.00 USD
5/15/20265.00 USD
5/14/20264.80 USD
5/13/20264.65 USD
5/12/20264.65 USD
5/11/20264.65 USD
5/8/20264.46 USD
5/7/20264.75 USD
5/6/20264.75 USD
5/5/20264.96 USD
5/4/20264.85 USD
5/3/20264.85 USD
5/1/20264.85 USD
4/30/20264.70 USD
4/29/20264.80 USD
4/28/20264.88 USD
4/27/20264.35 USD
4/24/20264.35 USD
4/23/20264.35 USD
4/21/20264.30 USD
4/20/20264.30 USD
4/17/20264.21 USD
4/16/20264.31 USD
4/15/20264.20 USD
4/14/20264.49 USD
4/13/20264.21 USD
4/10/20264.50 USD
4/9/20264.28 USD
4/8/20264.20 USD
4/7/20264.27 USD
4/6/20264.40 USD
4/2/20264.60 USD
3/27/20264.58 USD
3/26/20264.65 USD
3/25/20264.65 USD
3/23/20264.60 USD
3/20/20264.50 USD
3/19/20264.55 USD
3/17/20264.65 USD
3/16/20264.55 USD
3/15/20264.55 USD
3/13/20264.84 USD
3/11/20264.50 USD
3/10/20264.35 USD
3/9/20264.65 USD
3/6/20264.26 USD
3/4/20264.26 USD
3/3/20264.55 USD
2/25/20264.50 USD
2/23/20264.30 USD
2/19/20264.50 USD
2/18/20264.50 USD
2/16/20264.30 USD
2/13/20264.30 USD
2/11/20264.50 USD
2/10/20264.51 USD
2/9/20264.56 USD
2/5/20264.74 USD
2/3/20264.60 USD
2/2/20264.65 USD
2/1/20264.80 USD
1/29/20264.76 USD
1/28/20264.50 USD
1/27/20264.91 USD
1/25/20264.90 USD
1/23/20264.90 USD
1/21/20264.93 USD
1/20/20264.60 USD
1/16/20264.60 USD
1/15/20264.89 USD
1/14/20264.75 USD
1/12/20264.78 USD
1/9/20264.65 USD
1/8/20264.85 USD
1/5/20264.85 USD
1/1/20264.55 USD
12/31/20254.65 USD
12/30/20254.55 USD
12/29/20254.55 USD
12/26/20254.50 USD
12/24/20254.50 USD
12/23/20254.50 USD
12/22/20254.50 USD
12/19/20254.83 USD
12/18/20254.90 USD
12/17/20254.90 USD
12/16/20255.00 USD
12/15/20255.00 USD
12/12/20254.95 USD
12/11/20254.90 USD
12/9/20254.87 USD
12/8/20254.85 USD
12/7/20254.95 USD
12/5/20254.80 USD
12/3/20254.85 USD
12/2/20254.80 USD
12/1/20254.75 USD
11/30/20254.82 USD
11/28/20255.00 USD
11/26/20254.85 USD
11/24/20254.95 USD
11/23/20254.85 USD
11/21/20254.85 USD
11/19/20254.65 USD
11/18/20254.65 USD
11/17/20254.65 USD
11/16/20254.75 USD
11/13/20254.80 USD
11/12/20254.90 USD
11/11/20254.92 USD
11/10/20254.80 USD
11/9/20254.75 USD
11/7/20254.80 USD
11/5/20255.00 USD
11/4/20254.80 USD
11/3/20254.80 USD
11/2/20254.80 USD
10/31/20254.80 USD
10/29/20254.80 USD
10/28/20254.80 USD
10/27/20254.70 USD
10/24/20254.75 USD
10/23/20254.75 USD
10/22/20254.75 USD
10/21/20254.74 USD
10/20/20254.75 USD
10/17/20254.75 USD
10/16/20254.00 USD
10/14/20254.72 USD
10/13/20254.75 USD
10/10/20254.83 USD
10/9/20254.60 USD
10/8/20254.80 USD
10/7/20254.80 USD
10/6/20254.70 USD
10/3/20254.70 USD
10/2/20254.70 USD
10/1/20254.70 USD
9/30/20254.80 USD
9/29/20254.65 USD
9/25/20254.65 USD
9/24/20254.25 USD
9/23/20254.70 USD
9/22/20254.70 USD
9/19/20254.66 USD
9/18/20254.65 USD
9/17/20254.75 USD
9/16/20254.75 USD
9/15/20254.65 USD
9/12/20254.65 USD
9/11/20254.60 USD
9/10/20254.60 USD
9/9/20254.80 USD
9/8/20254.85 USD
9/5/20254.86 USD
9/4/20254.95 USD
9/3/20254.95 USD
9/2/20255.25 USD
8/29/20254.90 USD
8/28/20254.93 USD
8/27/20254.94 USD
8/26/20254.95 USD
8/25/20254.85 USD
8/22/20254.85 USD
8/21/20254.85 USD
8/20/20254.90 USD
8/19/20254.80 USD
8/18/20254.65 USD
8/15/20254.60 USD
8/14/20254.60 USD
8/13/20254.85 USD
8/12/20254.65 USD
8/11/20254.65 USD
8/8/20254.65 USD
8/7/20254.70 USD
8/6/20254.75 USD
8/5/20254.75 USD
8/4/20254.85 USD
8/1/20254.85 USD
7/30/20254.90 USD
7/29/20254.68 USD
7/28/20254.65 USD
7/27/20254.68 USD
7/25/20254.65 USD
7/24/20254.83 USD
7/23/20254.65 USD
7/22/20254.60 USD
7/21/20255.00 USD
Access this data via the Eulerpool API
Get Free API Key

Veradigm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.50 B USD
-56.00 M USD
700.40 M USD
Jan 1, 2021
1.50 B USD
89.00 M USD
134.40 M USD
Jan 1, 2022
588.02 M USD
-19.05 M USD
-86.46 M USD
Jan 1, 2023 (e)
630.46 M USD
82.69 M USD
80.35 M USD
Jan 1, 2024 (e)
616.66 M USD
46.56 M USD
39.99 M USD
Jan 1, 2025 (e)
596.34 M USD
39.47 M USD
29.44 M USD
Jan 1, 2026 (e)
822.17 M USD
241.03 M USD
60.27 M USD
Jan 1, 2027 (e)
788.26 M USD
141.78 M USD
119.96 M USD

Veradigm Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 21, 2026, 11:26 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023e2024e2025e2026e2027e2028e2029e
1.381.391.391.501.621.631.501.500.590.630.620.600.820.790.660.69
0.290.65–8.018.020.93-7.970.07-60.887.14-2.22-3.2537.92-4.14-16.755.79
39.6541.8543.3642.2238.4037.3837.6241.1852.3852.3852.3852.3852.3852.3852.3852.38
546.00580.00601.00632.00621.00610.00565.00619.00308.00330.00322.67312.19430.57412.76343.62363.52
-36.0033.0072.0012.00-96.00-63.00-56.0089.00-19.0082.0046.0039.00241.00141.0086.00103.00
-2.612.385.190.80-5.94-3.86-3.735.92-3.2313.027.476.5429.3217.8913.1114.84
-66.00-2.00-25.00-196.00363.00-182.00700.00134.00-86.0080.0039.0029.0060.00119.0059.0074.00
-36.54-96.971,150.00684.00-285.20-150.14-484.62-80.86-164.18-193.02-51.25-25.64106.9098.33-50.4225.42
179.80185.10186.20180.80176.00166.30159.30138.70112.08112.08112.08112.08112.08112.08112.08112.08
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Veradigm generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Veradigm retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Veradigm's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Veradigm has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Veradigm's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Veradigm stock margins

The Veradigm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Veradigm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Veradigm.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
38.41 %
-5.98 %
22.48 %
Jan 1, 2019
37.38 %
-3.87 %
-11.16 %
Jan 1, 2020
37.65 %
-3.73 %
46.61 %
Jan 1, 2021
41.22 %
5.92 %
8.94 %
Jan 1, 2022
52.45 %
-3.24 %
-14.70 %
Jan 1, 2023 (e)
52.45 %
13.12 %
12.74 %
Jan 1, 2024 (e)
52.45 %
7.55 %
6.48 %
Jan 1, 2025 (e)
52.45 %
6.62 %
4.94 %

Veradigm Stock Revenue, EBIT, Earnings per Share

The Veradigm earnings per share therefore indicates how much revenue Veradigm has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
9.19 USD
-0.55 USD
2.07 USD
Jan 1, 2019
9.82 USD
-0.38 USD
-1.10 USD
Jan 1, 2020
9.43 USD
-0.35 USD
4.40 USD
Jan 1, 2021
10.84 USD
0.64 USD
0.97 USD
Jan 1, 2022
5.25 USD
-0.17 USD
-0.77 USD
Jan 1, 2023 (e)
5.79 USD
0.74 USD
0.74 USD
Jan 1, 2024 (e)
5.66 USD
0.42 USD
0.37 USD
Jan 1, 2025 (e)
5.48 USD
0.35 USD
0.27 USD

Veradigm business model & stock analysis

Allscripts Healthcare Solutions Inc is one of the leading companies in the digital healthcare sector in the USA. The company was founded in 1982 and has since become one of the most important providers of IT solutions in healthcare. Allscripts supports healthcare providers in improving patient care and efficiency through the development and provision of innovative software and IT solutions. The business model of Allscripts is based on the development and sale of web-based software solutions for medical documentation and hospital management. These solutions are mainly distributed to hospitals and practices through subscriptions or licenses. Allscripts offers a variety of products that focus on various areas of medical care. One of the main divisions of the company is the electronic health records system (EHR). This system allows for the electronic recording, storage, and management of medical data and information. This enables healthcare providers to quickly and easily access patient information and document important diagnoses and treatments. Another important division of Allscripts is the Revenue Cycle Management (RCM), which optimizes billing and payment processes in hospitals and practices. In addition, Allscripts also offers solutions for telemedicine, including patient portal applications, remote patient monitoring systems, and mobile apps for patients and providers. Allscripts is based in Chicago and employs over 10,000 employees in various countries. The company also maintains partnerships with other companies in healthcare to facilitate and improve the complexity of digital transformation in the healthcare market. This includes companies like Microsoft, who work together with Allscripts on the development of artificial intelligence for healthcare applications. Allscripts' portfolio of offerings is very broad and provides customers with a variety of software solutions for different areas of medical care. The products are particularly characterized by their user-friendly interfaces, flexibility, and scalability. This allows customers to customize the solutions to their specific needs and consider future requirements. However, some products have been criticized for their expandability, poor design, and slow loading times. Recently, Allscripts has made a number of investments in research and development to address these issues and optimize the applications. In summary, Allscripts Healthcare Solutions Inc is considered one of the leading providers of software and IT solutions in healthcare in the USA. Thanks to a wide range of products and close collaboration with partners in healthcare, Allscripts is able to offer its customers innovative and scalable solutions that help them optimize their business processes and improve the quality of their medical care.

Veradigm SWOT Analysis

Strengths

1. Strong Reputation: Allscripts Healthcare Solutions Inc has established itself as a reputable and trusted provider of healthcare solutions in the industry.

2. Comprehensive Product Portfolio: The company offers a wide range of healthcare software products and services, including electronic health records (EHRs) and practice management systems.

3. Established Customer Base: Allscripts has a large and diverse customer base, including healthcare organizations of varying sizes and specialties.

Weaknesses

1. Intense Competition: Allscripts faces significant competition from other healthcare software companies, which may impact its market share and pricing power.

2. Reliance on Third-Party Systems: The company's software solutions often integrate with third-party systems, which can introduce risks related to interoperability and compatibility.

3. Limited Global Presence: Allscripts' market presence outside of the United States is relatively small compared to some of its competitors.

Opportunities

1. Growing Healthcare IT Market: The increasing digitization of healthcare and the demand for efficient solutions present opportunities for Allscripts to expand its customer base.

2. Expansion into Telehealth: The COVID-19 pandemic has accelerated the adoption of telehealth. Allscripts can explore opportunities to enhance its telehealth capabilities and tap into this growing market.

3. Strategic Partnerships: Collaborating with healthcare providers, technology companies, and other stakeholders can enable Allscripts to develop innovative solutions and expand its market reach.

Threats

1. Regulatory Changes: Frequent changes in healthcare regulations can create challenges for Allscripts in terms of compliance and adapting its software to new requirements.

2. Data Security Risks: The increasing volume and sensitivity of healthcare data pose significant risks in terms of data breaches and cybersecurity threats.

3. Economic Uncertainty: Economic downturns or budget constraints within the healthcare industry can impact the purchasing decisions of potential customers, affecting Allscripts' revenue.

Veradigm Segments

Veradigm Revenue by Segment (1/5)

  • 3 Years

  • 5 Years

  • Max

Software delivery, Support and Maintenance
Client services
Details
Date
Software delivery, Support and Maintenance
Client services
Payer and Life Science
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
1.84 M USD
-8.58 M USD
0.00 USD
Jan 1, 2021
916.19 M USD
586.85 M USD
0.00 USD

Veradigm Revenue by Segment (2/5)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Provider
Payer & Life Sciences
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD

Veradigm Revenue by Segment (3/5)

  • 3 Years

  • Max

Hospitals and Large Physician Practices
Veradigm
Details
Date
Hospitals and Large Physician Practices
Veradigm
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2021
927.59 M USD
552.21 M USD

Veradigm Revenue by Segment (4/5)

  • 3 Years

  • 5 Years

  • Max

Clinical and financial solutions
Netsmart
Population health
Details
Date
Clinical and financial solutions
Netsmart
Population health
Jan 1, 2016
1.13 B USD
173.36 M USD
235.21 M USD
Jan 1, 2017
1.25 B USD
0.00 USD
270.45 M USD
Jan 1, 2018
1.57 B USD
0.00 USD
190.71 M USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD

Veradigm Revenue by Segment (5/5)

  • 3 Years

  • 5 Years

  • Max

Netsmart
Details
Date
Netsmart
Jan 1, 2016
0.00 USD
Jan 1, 2017
319.07 M USD
Jan 1, 2018
0.00 USD
Jan 1, 2021
0.00 USD

Veradigm Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Other International
Canada
Details
Date
United States
Other International
Canada
Jan 1, 2016
1.50 B USD
30.58 M USD
18.69 M USD
Jan 1, 2017
1.75 B USD
41.05 M USD
15.82 M USD
Jan 1, 2018
1.70 B USD
37.41 M USD
15.38 M USD
Jan 1, 2019
1.70 B USD
54.01 M USD
16.50 M USD
Jan 1, 2020
1.44 B USD
47.34 M USD
15.62 M USD
Jan 1, 2021
1.43 B USD
53.72 M USD
16.01 M USD
Jan 1, 2022
588.02 M USD
0.00 USD
0.00 USD

Veradigm Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Veradigm historical P/E ratio, EBIT multiple, and P/S ratio

Veradigm annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Veradigm shares outstanding

The number of shares of Veradigm was 112.08 M in 2025. This indicates how many shares Veradigm is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
176.00 M Stocks
Jan 1, 2019
166.30 M Stocks
Jan 1, 2020
159.30 M Stocks
Jan 1, 2021
138.70 M Stocks
Jan 1, 2022
112.08 M Stocks
Jan 1, 2023 (e)
112.08 M Stocks
Jan 1, 2024 (e)
112.08 M Stocks
Jan 1, 2025 (e)
112.08 M Stocks

Current Veradigm forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy60.00 % (6)
Hold40.00 % (4)
Sell0.00 % (0)
12M Price Target
5.10
Last Price
4.80
Currency
USD
12M Return Potential
6.25 %
LTM Return
0 %

Veradigm Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
3/16/20260.07USD150.55 MUSD2025 Q4
8/2/20230.22USD162.96 MUSD2023 Q2
5/3/20230.20USD153.91 MUSD2023 Q1
2/22/20230.27USD171.02 MUSD2022 Q4
11/3/20220.19USD155.10 MUSD2022 Q3
8/4/20220.15USD150.09 MUSD2022 Q2
5/5/20220.22USD330.46 MUSD2022 Q1
2/24/20220.33USD396.97 MUSD2021 Q4
11/4/20210.19USD381.02 MUSD2021 Q3
8/5/20210.18USD379.06 MUSD2021 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Veradigm stock

39/100
9
Environment
42
Social
68
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Veradigm shareholder structure

% Name
19.41413%
Stonehill Capital Management LLC
Stonehill Capital Management LLC
7.95179%
Silver Point Capital, L.P.
Silver Point Capital, L.P.
4.71475%
Kent Lake PR LLC
Kent Lake PR LLC
3.58127%
TD Securities (USA) LLC
TD Securities (USA) LLC
2.97790%
Madison Avenue Partners LP
Madison Avenue Partners LP
1.27547%
Wellington Management Company, LLP
Wellington Management Company, LLP
...

Veradigm Executives and Management Board

TV

Ms. Tejal Vakharia

(49)

Senior Vice President, General Counsel - Marketing and Government Affairs

Compensation2.08 M USD
DS

Mr. Dave Stevens

(60)

Independent Director

Compensation281,500.00 USD
CZ

Ms. Carol Zierhoffer

(62)

Lead Independent Director

Compensation277,500.00 USD
LS

Mr. Louis Silverman

(66)

Independent Chairman of the Board

DT

Mr. Donald Trigg

(54)

Chief Executive Officer, Director · since 2025

Veradigm Supply Chain

Veradigm Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
18 companies
#Name1M3M6M1Y2YTrend
1
UnitedHealth Group
Supplier
0.79
0.68
0.64
0.73
0.83
2
Pure Storage A
Supplier
0.94
0.85
0.34
0.38
0.71
3
RELX
Supplier
0.86
0.26
0.11
0.30
0.68
4
Microsoft
Supplier
0.15
0.59
-0.47
-0.02
0.67
5
Wolters Kluwer
Supplier
0.56
0.38
-0.24
-0.07
0.61
#Name1M3M6M1Y2YTrend
1
Vocera Communications, Inc.
Supplier
-0.77
-0.45
0.37
0.66
—
2
Oneview Health CDIs
Supplier
0.63
-0.57
-0.50
-0.67
—
3
Nuance Communications Incorporated
Supplier
-0.40
-0.52
-0.11
0.06
—
4
SOC Telemed A
Supplier
-0.79
-0.24
-0.15
-0.29
—
5
Atos
Supplier
-0.12
0.11
-0.53
-0.73
-0.79

Frequently asked questions about Veradigm

Allscripts Healthcare Solutions Inc is a leading healthcare technology company that provides innovative solutions and services to healthcare organizations. The business model of Allscripts revolves around the development and provision of electronic health record (EHR) systems, practice management software, and other healthcare IT solutions. By offering integrated platforms, Allscripts enables healthcare providers to streamline operations, improve patient care, and enhance clinical outcomes. With a focus on promoting interoperability and connectivity, Allscripts facilitates efficient data exchange across healthcare settings. By leveraging technology and data analytics, Allscripts aims to optimize workflows, enhance decision-making processes, and ultimately improve the overall delivery of healthcare services.

All fundamentals and in-depth analysis of Veradigm

Our stock analysis for Veradigm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veradigm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Veradigm Stock
Veradigm Revenue→
Veradigm Stock
Veradigm Net Income→
Veradigm Stock
Veradigm P/E→
Veradigm Stock
Veradigm P/S→
Veradigm Stock
Veradigm EBIT→
Veradigm Stock
Veradigm Dividend→
Veradigm Stock
Veradigm Directors Dealings→
Veradigm Stock
Veradigm Stocks→
Veradigm Stock
Veradigm Market capitalization→
Veradigm Stock
Veradigm Debt→
Veradigm Stock
Veradigm Liabilities→
Veradigm Stock
Veradigm Equity→
Veradigm Stock
Veradigm AAQS→
Veradigm Stock
Veradigm Employees→
Veradigm Stock
Veradigm ROE→
Veradigm Stock
Veradigm ROA→
Veradigm Stock
Veradigm ROCE→
Veradigm Stock
Veradigm News→
Veradigm Stock
Veradigm Analyst Price Targets→

Health Stocks

VerastemVeracyteVericelVera TherapeuticsVerisante TechnologyVenus RemediesVerrica PharmaceuticalsVenus Medtech HangzhouVertex PharmaceuticalsVentriPoint DiagnosticsVetnostrum Animal Health CoVeeva SystemsAll Stocks A–Z →